CRYO-CELL International Inc. is a leading biotechnology company that specializes in the collection, processing, and cryogenic preservation of umbilical cord blood stem cells for family use. CRYO-CELL was founded in 1989 and was the world's first cord blood stem cell bank. The Florida-based company has consistently been ahead of the curve in the biotech industry, holding more than two decades of experience in the field of stem cell preservation.
CRYO-CELL operates in conformity with the highest standards of regulatory compliance and is accredited by the AABB (formerly known as the American Association of Blood Banks). Its state-of-the-art facility provides an environment of maximum security and safety for the crucial stem cell deposits of its customers.
Over the years, cord blood stem cells preserved by CRYO-CELL have been used in more than 500 transplants. These stem cells are proven to be effective in treating various life-threatening diseases, including leukemia, certain types of tumors, anemias, lymphoma, and immune disorders.
CRYO-CELL International has also developed what it calls the CélleSM service, which allows women to harvest and preserve stem cells from their menstrual blood for potential future therapeutic use. This service reflects the company's commitment to innovation and to providing value for its customers.
In addition to its activities in the United States, CRYO-CELL International Inc. operates in over 90 countries worldwide through its various affiliates and licensees. Its global footprint expands the reach of its important work beyond the borders of its home country, helping families around the world access potentially life-saving stem cell preservation services.
The company has a commitment to public education about the potential of cord blood and other sources of stem cells, and it continuously works to raise awareness about the lifesaving potential of these cells.
The company is listed on the OTCQB marketplace under the ticker symbol "CCEL". CRYO-CELL is regarded favourably for its competitiveness and the quality of its services. The company's focus on scientific excellence, coupled with its commitment to setting the highest standards in the industry, continues to secure its position as a driving force in cord blood banking worldwide. The combination of pioneering technologies, robust business strategies, and committed professionals is what makes CRYO-CELL International noteworthy in the biotech industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
_07_03_2026_03_50_21_133108.jpg)
CRYO CELL INTERNATIONAL INC. (AMEX: CCEL) has announced that its annual stockholder meeting will be held on October 27, 2026, with September 21, 2026, as the record date for voting eligibility. The deadline for stockholders to submit business proposals or director nominations was July 27, 2026. David Portnoy, chairman and co-CEO, signed the company's official report on September 14, 2026.
The global stem cell umbilical cord blood market is projected to grow from USD 19.49 billion in 2026 to USD 30.16 billion by 2035, exhibiting a CAGR of 4.97%. This growth is driven by the increasing demand for regenerative medicine and advanced therapies, with North America dominating the market and Asia Pacific showing the fastest growth. Key segments include private cord blood banks by storage type and cancer treatment by application, while AI is revolutionizing the field by improving research and clinical applications.